• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday

    6/20/24 10:21:23 AM ET
    $ACN
    $AMD
    $APLD
    $BILI
    Real Estate
    Real Estate
    Semiconductors
    Technology
    Get the next $ACN alert in real time by email

    U.S. stocks were mixed, with the Dow Jones index gaining around 150 points on Thursday.

    Shares of KB Home (NYSE:KBH) rose during Thursday's session as the company posted better-than-expected earnings and sales results for its second quarter on Tuesday.

    KB Home reported quarterly earnings of $2.15 per share, which beat the analyst consensus estimate of $1.78. Quarterly sales came in at $1.71 billion, which beat the analyst consensus estimate of $1.651 billion, according to data from Benzinga Pro.

    KB Home shares gained 4.2% to $70.91 on Thursday.

    Here are some other big stocks recording gains in today’s session.

    • Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares climbed 16% to $6.36 after TD Cowen upgraded the stock from Hold to Buy and raised its price target from $7 to $11.
    • Applied Digital Corporation (NASDAQ:APLD) jumped 15.3% to $5.95.
    • Ranpak Holdings Corp. (NYSE:PACK) rose 13.7% to $6.49.
    • ImmunityBio, Inc. (NASDAQ:IBRX) gained 13.6% to $7.08 after the company announced insurance coverage of ANKTIVA across multiple states with first commercial doses administered.
    • Harrow, Inc. (NASDAQ:HROW) shares jumped 12.2% to $19.81 after the company announced the manufacture of the first of three commercial-scale process performance qualification batches of TRIESENCE 40 mg/mL. Also the company announced that the second and third required PPQ batches are now scheduled.
    • ZKH Group Limited (NYSE:ZKH) climbed 11.4% to $3.92
    • NANO Nuclear Energy Inc. (NASDAQ:NNE) rose 11.3% to $12.91.
    • Himax Technologies, Inc. (NASDAQ:HIMX) surged 11.1% to $8.23
    • Globant S.A. (NYSE:GLOB) gained 7.9% to $166.36 after the company announced the launch of Globant GUT.
    • Bilibili Inc. (NASDAQ:BILI) shares jumped 7.8% to $17.45. On Tuesday, JP Morgan analyst Daniel Chen upgraded Bilibili from Neutral to Overweight and announced a $21 price target.
    • Super Micro Computer, Inc. (NASDAQ:SMCI) climbed 7% to $982.60 after Elon Musk indicated the company will provide server racks for the supercomputer that xAI is building.
    • Accenture plc (NYSE:ACN) gained 6.7% to $304.41 after the company posted quarterly results.
    • ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) rose 6.2% to $20.18.
    • WestRock Company (NYSE:WRK) rose 5.6% to $52.48.
    • Advanced Micro Devices, Inc. (NASDAQ:AMD) gained 5% to $162.36.
    • Kohl’s Corporation (NYSE:KSS) climbed 4.5% to $22.35.
    • Gilead Sciences, Inc. (NASDAQ:GILD) rose 4.1% to $65.76 after the company announced results from an interim analysis of a Phase 3 trial, showing Lenacapavir demonstrated 100% efficacy for HIV prevention and superiority to daily Truvada.

    Now Read This: Top 4 Consumer Stocks that May Keep You Up At Night This Month

    Get the next $ACN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACN
    $AMD
    $APLD
    $BILI

    CompanyDatePrice TargetRatingAnalyst
    Bilibili Inc.
    $BILI
    3/27/2026$27.00Neutral → Buy
    Citigroup
    KB Home
    $KBH
    3/24/2026$77.00Mkt Outperform
    Citizens
    Super Micro Computer Inc.
    $SMCI
    3/23/2026$22.00Outperform → Market Perform
    Northland Capital
    Super Micro Computer Inc.
    $SMCI
    3/20/2026Buy → Hold
    Argus
    Super Micro Computer Inc.
    $SMCI
    3/20/2026Market Perform → Market Underperform
    CJS Securities
    Accenture plc
    $ACN
    3/20/2026$220.00Reduce → Hold
    HSBC Securities
    Bilibili Inc.
    $BILI
    3/17/2026$35.00Neutral → Overweight
    Analyst
    ImmunityBio Inc.
    $IBRX
    3/12/2026$13.00Buy
    BTIG Research
    More analyst ratings

    $ACN
    $AMD
    $APLD
    $BILI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

    11/15/24 4:36:27 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACN
    $AMD
    $APLD
    $BILI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bilibili upgraded by Citigroup with a new price target

    Citigroup upgraded Bilibili from Neutral to Buy and set a new price target of $27.00

    3/27/26 9:03:14 AM ET
    $BILI
    EDP Services
    Technology

    Citizens initiated coverage on KB Home with a new price target

    Citizens initiated coverage of KB Home with a rating of Mkt Outperform and set a new price target of $77.00

    3/24/26 8:47:39 AM ET
    $KBH
    Homebuilding
    Consumer Discretionary

    Super Micro Computer downgraded by Northland Capital with a new price target

    Northland Capital downgraded Super Micro Computer from Outperform to Market Perform and set a new price target of $22.00

    3/23/26 8:27:58 AM ET
    $SMCI
    Computer Manufacturing
    Technology

    $ACN
    $AMD
    $APLD
    $BILI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lindstrom Richard L Md bought $461,354 worth of shares (60,229 units at $7.66), increasing direct ownership by 32% to 246,933 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/24/26 6:13:03 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Chief Commercial Officer Guido Philip bought $999,328 worth of shares (8,800 units at $113.56), increasing direct ownership by 26% to 42,322 units (SEC Form 4)

    4 - ADVANCED MICRO DEVICES INC (0000002488) (Issuer)

    5/22/25 4:14:05 PM ET
    $AMD
    Semiconductors
    Technology

    Director Lindstrom Richard L Md bought $69,600 worth of shares (10,000 units at $6.96), increasing direct ownership by 6% to 172,704 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    5/12/25 8:50:46 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACN
    $AMD
    $APLD
    $BILI
    SEC Filings

    View All

    Amendment: Applied Digital Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K/A - Applied Digital Corp. (0001144879) (Filer)

    4/1/26 7:00:38 AM ET
    $APLD
    Finance: Consumer Services
    Finance

    ImmunityBio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Regulation FD Disclosure

    8-K - ImmunityBio, Inc. (0001326110) (Filer)

    3/31/26 8:24:54 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Bilibili Inc.

    6-K - Bilibili Inc. (0001723690) (Filer)

    3/31/26 8:25:08 AM ET
    $BILI
    EDP Services
    Technology

    $ACN
    $AMD
    $APLD
    $BILI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gilead Extends Tender Offer to Acquire Arcellx

    Gilead Sciences, Inc. (NASDAQ:GILD) today extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx. The offer remains at a purchase price of (1) $115.00 per share, net to the seller in cash, without interest, subject to any withholding tax, plus (2) one contractual contingent value right (CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, payable on March 31, 2030, subject to cumulative worldwide sales of Arcellx's anitocabtagene autoleucel (anito-cel) product exceeding $6.0 billion on or prior to December 31, 2029. The tender offer, which was pr

    4/1/26 4:13:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April

    BEDFORD, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in April 2026. Ocular plans to present additional data and analyses from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD). Upcoming Scientific Conferences: 14th Annual Vit-Buckle Society (VBS) Meeting: April 9 - 11, 2026Las Vegas, Nevada Symposium Title: Redefining the Management of Neovascular AMDSymposium Date/Time: Saturday, Ap

    4/1/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline

    ImmunityBio to receive $75 million in non-dilutive funding under existing Revenue Interest Purchase Agreement (RIPA) with Oberland Capital, bringing total committed capital to $375 million Simultaneously conversion of $25 million of the outstanding promissory note held by Nant Capital, an entity affiliated with Executive Chairman bolstering ImmunityBio's balance sheet with reduction in the debt Proceeds strengthen ImmunityBio's balance sheet and support global expansion following recent approvals, while advancing company's broader immunotherapy pipeline ImmunityBio, Inc. ((IBRX), a vertically integrated, commercial-stage immunotherapy company, today announced it has secured $75 mi

    3/31/26 7:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACN
    $AMD
    $APLD
    $BILI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Timm Jill

    4 - KOHLS Corp (0000885639) (Issuer)

    4/1/26 5:44:03 PM ET
    $KSS
    Department/Specialty Retail Stores
    Consumer Discretionary

    SEC Form 4 filed by Steinmetz Mari

    4 - KOHLS Corp (0000885639) (Issuer)

    4/1/26 5:38:54 PM ET
    $KSS
    Department/Specialty Retail Stores
    Consumer Discretionary

    SEC Form 4 filed by Raymond Christie

    4 - KOHLS Corp (0000885639) (Issuer)

    4/1/26 5:33:21 PM ET
    $KSS
    Department/Specialty Retail Stores
    Consumer Discretionary

    $ACN
    $AMD
    $APLD
    $BILI
    Leadership Updates

    Live Leadership Updates

    View All

    Super Micro Computer Announces Resignation of Board Member Yih-Shyan "Wally" Liaw

    DeAnna Luna Appointed Acting Chief Compliance OfficerSAN JOSE, Calif., March 20, 2026 /PRNewswire/ -- Super Micro Computer, Inc. (NASDAQ:SMCI) ("Supermicro" or the "Company") today announced that Yih-Shyan "Wally" Liaw ("Mr. Liaw") has resigned from the Company's Board of Directors, effective immediately. Following Mr. Liaw's resignation, the Company's Board comprises eight directors. There are no changes to the Board's committee structure. The Company also announced today that it has appointed DeAnna Luna as acting Chief Compliance Officer, effective immediately. Ms. Luna brings to this role more than two decades of experience in global trade compliance, governance, highly regulated markets

    3/20/26 4:38:00 PM ET
    $SMCI
    Computer Manufacturing
    Technology

    ZIM Updates on Withholding Tax Procedures on March 2026 Cash Dividend

    HAIFA, Israel, March 19, 2026 /PRNewswire/ -- ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) ("ZIM" or the "Company"), a global container liner shipping company, hereby updates that in connection with the dividend distribution expected to take place on March 26, 2026, as previously announced by the Company on March 9, 2026 (the "Dividend"), the previously obtained tax ruling from the Israeli Tax Authority ("ITA") on tax withholding procedures relating to the payment of the Dividend to the Company's shareholders (the "Ruling"), as extended, shall apply.   As a result of the Ruling, certain shareholders of the Company ("Shareholders") may be eligible to a reduced Israeli withholding tax rate

    3/19/26 7:00:00 AM ET
    $ZIM
    Marine Transportation
    Consumer Discretionary

    Kohl's Corporation Declares Quarterly Dividend

    The Board of Directors of Kohl's Corporation (NYSE:KSS) ("Kohl's" or the "Company") today declared a regular quarterly dividend of $0.125 per share on the Company's common stock. The dividend is payable April 1, 2026, to shareholders of record at the close of business on March 18, 2026. About Kohl's Kohl's (NYSE:KSS) is a leading omnichannel retailer built on a foundation that combines great brands, incredible value and convenience for our customers. Kohl's is uniquely positioned to deliver against its long-term strategy and its purpose to take care of families' realest moments. Kohl's serves millions of families in its more than 1,100 stores in 49 states, online at Kohls.com, and throu

    2/25/26 4:15:00 PM ET
    $KSS
    Department/Specialty Retail Stores
    Consumer Discretionary

    $ACN
    $AMD
    $APLD
    $BILI
    Financials

    Live finance-specific insights

    View All

    KB HOME REPORTS 2026 FIRST QUARTER RESULTS

    Revenues of $1.08 Billion; Diluted Earnings Per Share of $.52Repurchased $50.0 Million of Common StockLOS ANGELES, March 24, 2026 /PRNewswire/ -- KB Home (NYSE:KBH) today reported results for its first quarter ended February 28, 2026. "With solid traffic in our communities, we generated year-over-year net order growth in our first quarter," said Jeffrey Mezger, Executive Chairman.  "In addition, we are now achieving our targeted mix of Built to Order net orders.  Our renewed focus on our core Built to Order strategy, combined with an anticipated favorable regional mix of homes d

    3/24/26 4:10:00 PM ET
    $KBH
    Homebuilding
    Consumer Discretionary

    Applied Digital Sets Fiscal Third Quarter 2026 Conference Call for Wednesday, April 8, 2026, at 5:00 p.m. Eastern Time

    DALLAS, March 19, 2026 (GLOBE NEWSWIRE) -- Applied Digital Corporation (NASDAQ:APLD) ("Applied Digital" or the "Company"), a leading designer, builder and operator of high-performance, sustainably engineered data centers and colocation services for Artificial Intelligence ("AI"), networking, and blockchain workloads, will host a conference call on Wednesday, April 8, 2026, at 5:00 p.m. Eastern Time to discuss its operations and financial results for the fiscal third quarter ended February 28, 2026. A press release detailing these results will be issued after the market closes on the same day. Applied Digital management will provide prepared remarks, followed by a question-and-answer perio

    3/19/26 4:05:00 PM ET
    $APLD
    Finance: Consumer Services
    Finance

    Accenture Reports Second-Quarter Fiscal 2026 Results

    Accenture delivers record new bookings, revenues at the top of the company's guided range, strong profitability and robust free cash flow; Company now expects full-year fiscal 2026 revenue growth to be 3% to 5% in local currency Accenture (NYSE:ACN) reported financial results for the second quarter of fiscal 2026 ended February 28, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260319857314/en/ All comparisons are to the second quarter of fiscal 2025, unless noted otherwise. Accenture Chair and CEO Julie Sweet "We delivered record second quarter bookings of $22.1 billion, including a record 41 clients with quarterly bo

    3/19/26 6:39:00 AM ET
    $ACN
    Real Estate

    $ACN
    $AMD
    $APLD
    $BILI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Harrow Inc.

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    12/5/24 7:08:52 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Applied Digital Corporation

    SC 13D/A - Applied Digital Corp. (0001144879) (Subject)

    11/29/24 4:20:07 PM ET
    $APLD
    Finance: Consumer Services
    Finance

    SEC Form SC 13G filed by ZIM Integrated Shipping Services Ltd.

    SC 13G - ZIM Integrated Shipping Services Ltd. (0001654126) (Subject)

    11/14/24 6:36:01 PM ET
    $ZIM
    Marine Transportation
    Consumer Discretionary